Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.47 Million USD | 87.36% |
| 2022 | -11.64 Million USD | -5691.04% |
| 2021 | -201 Thousand USD | 59.88% |
| 2020 | -501 Thousand USD | 90.5% |
| 2019 | -5.27 Million USD | 45.46% |
| 2018 | -9.67 Million USD | 41.22% |
| 2017 | -16.45 Million USD | 40.92% |
| 2016 | -27.84 Million USD | 28.6% |
| 2015 | -38.99 Million USD | -18.37% |
| 2014 | -32.94 Million USD | 4.23% |
| 2013 | -34.4 Million USD | -56.11% |
| 2012 | -22.03 Million USD | -2.95% |
| 2011 | -21.4 Million USD | 3.01% |
| 2010 | -22.07 Million USD | -14.86% |
| 2009 | -19.21 Million USD | 61.63% |
| 2008 | -50.08 Million USD | -300.14% |
| 2007 | -12.51 Million USD | -20.58% |
| 2006 | -10.38 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.12 Million USD | -279.41% |
| 2024 Q2 | -62 Thousand USD | 97.08% |
| 2023 Q4 | 1.18 Million USD | -36.08% |
| 2023 Q3 | 1.85 Million USD | 253.48% |
| 2023 FY | -1.47 Million USD | 87.36% |
| 2023 Q1 | -3.3 Million USD | -56.64% |
| 2023 Q2 | -1.2 Million USD | 63.42% |
| 2022 Q2 | -1.97 Million USD | 52.4% |
| 2022 Q4 | -2.1 Million USD | 38.2% |
| 2022 Q1 | -4.14 Million USD | -50.69% |
| 2022 Q3 | -3.41 Million USD | -72.8% |
| 2022 FY | -11.64 Million USD | -5691.04% |
| 2021 Q4 | -2.75 Million USD | -36.1% |
| 2021 Q2 | 7 Million USD | 388.19% |
| 2021 Q1 | -2.43 Million USD | -1504.62% |
| 2021 FY | -201 Thousand USD | 59.88% |
| 2021 Q3 | -2.02 Million USD | -128.87% |
| 2020 Q1 | 218 Thousand USD | -84.72% |
| 2020 Q2 | -1.29 Million USD | -695.87% |
| 2020 Q3 | 407 Thousand USD | 131.33% |
| 2020 Q4 | 173 Thousand USD | -57.49% |
| 2020 FY | -501 Thousand USD | 90.5% |
| 2019 Q2 | -3.59 Million USD | -157.35% |
| 2019 Q1 | -1.39 Million USD | -2037.5% |
| 2019 Q4 | 1.42 Million USD | 183.16% |
| 2019 FY | -5.27 Million USD | 45.46% |
| 2019 Q3 | -1.71 Million USD | 52.2% |
| 2018 Q3 | -2.19 Million USD | 20.99% |
| 2018 FY | -9.67 Million USD | 41.22% |
| 2018 Q1 | -4.76 Million USD | 16.89% |
| 2018 Q2 | -2.77 Million USD | 41.75% |
| 2018 Q4 | 72 Thousand USD | 103.28% |
| 2017 FY | -16.45 Million USD | 40.92% |
| 2017 Q4 | -5.73 Million USD | -50.01% |
| 2017 Q3 | -3.82 Million USD | -177.58% |
| 2017 Q2 | -1.37 Million USD | 75.0% |
| 2017 Q1 | -5.51 Million USD | -2.72% |
| 2016 Q4 | -5.36 Million USD | 25.93% |
| 2016 FY | -27.84 Million USD | 28.6% |
| 2016 Q1 | -8.79 Million USD | 9.95% |
| 2016 Q3 | -7.24 Million USD | -12.31% |
| 2016 Q2 | -6.44 Million USD | 26.63% |
| 2015 Q4 | -9.76 Million USD | -15.6% |
| 2015 FY | -38.99 Million USD | -18.37% |
| 2015 Q1 | -10.99 Million USD | -0.68% |
| 2015 Q2 | -9.8 Million USD | 10.86% |
| 2015 Q3 | -8.44 Million USD | 13.84% |
| 2014 Q2 | -5.95 Million USD | 19.96% |
| 2014 Q4 | -10.92 Million USD | -26.61% |
| 2014 Q3 | -8.62 Million USD | -44.76% |
| 2014 Q1 | -7.44 Million USD | 18.1% |
| 2014 FY | -32.94 Million USD | 4.23% |
| 2013 FY | -34.4 Million USD | -56.11% |
| 2013 Q2 | -9.33 Million USD | -13.12% |
| 2013 Q3 | -7.71 Million USD | 17.38% |
| 2013 Q4 | -9.08 Million USD | -17.79% |
| 2013 Q1 | -8.25 Million USD | -0.55% |
| 2012 Q2 | -4.49 Million USD | -8.82% |
| 2012 Q1 | -4.12 Million USD | 28.95% |
| 2012 Q4 | -8.21 Million USD | -57.66% |
| 2012 FY | -22.03 Million USD | -2.95% |
| 2012 Q3 | -5.2 Million USD | -15.94% |
| 2011 FY | -21.4 Million USD | 3.01% |
| 2011 Q3 | -6.25 Million USD | -27.02% |
| 2011 Q2 | -4.92 Million USD | -11.6% |
| 2011 Q1 | -4.41 Million USD | 26.96% |
| 2011 Q4 | -5.81 Million USD | 7.14% |
| 2010 Q2 | -5.69 Million USD | -35.03% |
| 2010 Q1 | -4.21 Million USD | 2.97% |
| 2010 Q4 | -6.04 Million USD | 1.24% |
| 2010 FY | -22.07 Million USD | -14.86% |
| 2010 Q3 | -6.11 Million USD | -7.48% |
| 2009 Q3 | -4.63 Million USD | 2.38% |
| 2009 Q4 | -4.34 Million USD | 6.24% |
| 2009 FY | -19.21 Million USD | 61.63% |
| 2009 Q1 | -5.49 Million USD | 18.77% |
| 2009 Q2 | -4.74 Million USD | 13.53% |
| 2008 Q1 | -33.52 Million USD | 0.0% |
| 2008 FY | -50.08 Million USD | -300.14% |
| 2008 Q3 | -5.26 Million USD | -16.0% |
| 2008 Q2 | -4.53 Million USD | 86.47% |
| 2008 Q4 | -6.75 Million USD | -28.42% |
| 2007 FY | -12.51 Million USD | -20.58% |
| 2007 Q1 | -2.97 Million USD | 0.0% |
| 2007 Q2 | -3.12 Million USD | -5.18% |
| 2006 FY | -10.38 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 99.054% |
| Theratechnologies Inc. | -10.62 Million USD | 86.158% |
| Safety Shot Inc | -12.18 Million USD | 87.927% |
| Cosmos Health Inc. | -21.83 Million USD | 93.262% |
| Cronos Group Inc. | -81.37 Million USD | 98.192% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 100.704% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 96.243% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 111.745% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 58.29% |
| ProPhase Labs, Inc. | -21.61 Million USD | 93.194% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 68.709% |
| Dynavax Technologies Corporation | -37.02 Million USD | 96.027% |
| Radius Health, Inc. | -3.92 Million USD | 62.522% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 41.516% |
| Alvotech | -354.86 Million USD | 99.585% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 69.26% |
| Alpha Teknova, Inc. | -35.56 Million USD | 95.864% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 99.077% |
| SCYNEXIS, Inc. | 72.66 Million USD | 102.024% |
| Harrow Health, Inc. | 580 Thousand USD | 353.621% |
| Biofrontera Inc. | -22.67 Million USD | 93.513% |
| DURECT Corporation | -36.88 Million USD | 96.012% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 72.082% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 103.132% |
| OptiNose, Inc. | -22.74 Million USD | 93.533% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 111.645% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 90.26% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 76.316% |
| SIGA Technologies, Inc. | 83.62 Million USD | 101.759% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 115.765% |
| Shineco, Inc. | -17.06 Million USD | 91.38% |
| Phibro Animal Health Corporation | 53.31 Million USD | 102.759% |
| Procaps Group S.A. | 52.32 Million USD | 102.811% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 82.741% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 68.945% |
| Viatris Inc. | 766.2 Million USD | 100.192% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 69.26% |
| Rockwell Medical, Inc. | -6.67 Million USD | 77.946% |
| Incannex Healthcare Limited | -30.04 Million USD | 95.103% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 72.002% |
| Tilray Brands, Inc. | -174.74 Million USD | 99.158% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 100.881% |
| PetIQ, Inc. | 60.01 Million USD | 102.451% |
| Silver Spike Investment Corp. | 7.34 Million USD | 120.041% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 100.586% |
| Journey Medical Corporation | -2.07 Million USD | 29.04% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 89.198% |
| Assertio Holdings, Inc. | -243.53 Million USD | 99.396% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 75.036% |
| Embecta Corp. | 221.5 Million USD | 100.664% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 92.663% |
| Procaps Group, S.A. | 38.97 Million USD | 103.774% |
| PainReform Ltd. | -9.58 Million USD | 84.652% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 98.933% |
| Hempacco Co., Inc. | -8.81 Million USD | 83.307% |
| Talphera, Inc. | -16.88 Million USD | 91.29% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 101.678% |
| Alvotech | -354.86 Million USD | 99.585% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 100.403% |
| Kamada Ltd. | 10.06 Million USD | 114.616% |
| Indivior PLC | -4 Million USD | 63.225% |
| Currenc Group, Inc. | -6.64 Million USD | 77.866% |
| Evoke Pharma, Inc. | -7.43 Million USD | 80.204% |
| Flora Growth Corp. | -50.35 Million USD | 97.079% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 92.663% |
| Evolus, Inc. | -49.23 Million USD | 97.012% |
| HUTCHMED (China) Limited | 18.37 Million USD | 108.005% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 100.747% |
| Akanda Corp. | -10.05 Million USD | 85.365% |